DHA supplementation for late onset Stargardt disease: NAT-3 study

BACKGROUND: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD). METHODS: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BC...

Descripción completa

Detalles Bibliográficos
Autores principales: Querques, Giuseppe, Benlian, Pascale, Chanu, Bernard, Leveziel, Nicolas, Coscas, Gabriel, Soubrane, Gisele, Souied, Eric H
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909886/
https://www.ncbi.nlm.nih.gov/pubmed/20668719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909886/
https://www.ncbi.nlm.nih.gov/pubmed/20668719

Ejemplares similares